Summary: Scientific American explains the rise in psychedelic-assisted therapy for the treatment of depression and other psychiatric indications. Author Austin Lim, Ph.D., outlines the current rise in depression and prescriptions for antidepressants, despite their lack of efficacy for many patients, and that, in terms of outcomes, “psychedelics in combination with psychotherapy are remarkably efficient at treating depression.” Lim also references MAPS’ cost-effectiveness study, which “predicts that psychedelic therapy for posttraumatic stress disorder could save each patient $100,000 over a 30-year window.”
Originally appearing here.